Arena Pharmaceuticals Announces Equity Investment by Merck and Extension and Expansion of Merck Collaboration
SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that Merck & Co., Inc. has extended and
increased the funding of research under their existing cardiovascular
collaboration until October 2007, and expanded the scope of the collaboration
to include a wider range of potential therapies for important cardiovascular
Merck also purchased $7.5 million of Arena common stock at a price of
$8.00 per share, which represents approximately a seventy percent premium to
yesterday's closing price.
Under the amended collaboration, Merck will fund $5.7 million a year for
collaboration research at Arena. The amendment also limits the circumstances
by which Merck can terminate the research funding and improves for Arena the
terms relating to royalties.
"Merck's equity investment and continued commitment to our cardiovascular
collaboration is a credit to our scientists and validates our GPCR
technologies," stated Jack Lief, Arena's President and Chief Executive
Officer. "Over the next few years, we look forward to working synergistically
with Merck to bring effective treatments for cardiovascular disease to the
"Merck is pleased with the progress the collaboration has achieved to
date," says Mervyn Turner, Ph.D., Senior Vice President Worldwide Licensing
and External Research. "We look forward to continuing our work with Arena in
this important area."
In October 2002, Arena and Merck entered into a collaboration focused on a
group of GPCR targets discovered by Arena and believed to represent novel
targets for cardiovascular disease. Arena announced in the first quarter of
2004 the achievement of a $4 million milestone and in the third quarter of
2004 the achievement of a $3 million milestone under this collaboration.
Arena will host a third quarter financial results and corporate update
conference call on Wednesday, October 20, 2004 at 5:00 p.m. Eastern Time
(2:00 p.m. Pacific Time), during which time Arena's management will discuss
the extension and expansion of this collaboration. The conference call may be
accessed by dialing (888) 273-9887 for domestic callers, and (612) 332-0634
for international callers. Please specify to the operator that you would like
to join the "Arena Pharmaceuticals Third Quarter Earnings Conference Call."
The conference call will be webcast live on Arena's website at
http://www.arenapharm.com, under the investor relations section, and will be
archived there for 30 days following the call. Please connect to Arena's
website several minutes prior to the start of the conference call to ensure
adequate time for any software download that may be necessary.
About Arena Pharmaceuticals
Arena is a biopharmaceutical company focusing on the discovery,
development and commercialization of drugs in four major therapeutic areas:
metabolic, cardiovascular, inflammatory and central nervous system diseases.
Arena is developing a broad pipeline of compounds that act on an important
class of drug targets called G protein-coupled receptors, or GPCRs, and that
are being developed using Arena's proprietary technologies, including CART
(Constitutively Activated Receptor Technology) and Melanophore. Arena also
has research collaborations with Merck, Fujisawa, Taisho and TaiGen for
products in a number of different indications. For additional information
about Arena, visit their website at http://www.arenapharm.com.
Certain statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. Such forward-looking
statements include statements about Arena's collaboration with Merck and
statements about Arena's strategy, technologies, preclinical and clinical
programs, ability to identify and develop drugs, future achievements, goals
and expectations, as well as other statements that are not historical facts.
For such statements, Arena claims the protection of the Private Securities
Litigation Reform Act of 1995. Actual events or results may differ materially
from Arena's expectations. Factors that could cause actual results to differ
materially from the forward-looking statements include, but are not limited
to, the timing, success and cost of Arena's research, out-licensing endeavors
and clinical studies, Arena's ability to obtain additional financing, and the
timing and receipt of payments and fees, if any, from Arena's collaborators.
Additional factors that could cause actual results to differ materially from
those stated or implied by Arena's forward-looking statements are disclosed in
Arena's SEC reports, including Arena's most recent quarterly report on Form
10-Q. These forward-looking statements represent Arena's judgment as of the
date of this release. Arena disclaims any intent or obligation to update
these forward-looking statements.
Arena Pharmaceuticals® and Arena® are registered service marks of the
company. CART is an unregistered service mark of the company.
Jack Lief, President & CEO
Susan Neath, Media & Investor Relations
Atkins + Associates
SOURCE Arena Pharmaceuticals, Inc.
Web site: http://www.arenapharm.com